Innate Pharma annual stock-based compensation
2017
2018
2019
2020
2021
2022
2023
2024
2025
Innate Pharma Stock-Based Compensation Growth & History (IPH)
Innate Pharma's stock-based compensation was €2.6M for fiscal 2025.
View full Innate Pharma company overviewInnate Pharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €2.6M | −€1.4M | −34.91% |
| 2024 | 2024-12-31 | €3.9M | −€312,000 | −7.33% |
| 2023 | 2023-12-31 | €4.3M | €7,000 | +0.16% |
| 2022 | 2022-12-31 | €4.2M | €1.6M | +62.36% |
| 2021 | 2021-12-31 | €2.6M | €142,000 | +5.74% |
| 2020 | 2020-12-31 | €2.5M | −€1.4M | −35.31% |
| 2019 | 2019-12-31 | €3.8M | €1.1M | +41.34% |
| 2018 | 2018-12-31 | €2.7M | −€7.3M | −72.89% |
| 2017 | 2017-12-31 | €10.0M | — | — |
Innate Pharma stock-based compensation trends
Over the last five fiscal years, Innate Pharma's stock-based compensation increased from €2.5M to €2.6M, a change of €92,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Innate Pharma source filings ↗